Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTRACE neoadjuvant and adjuvant sacituzumab govitecan plus zimberelimab in resectable non-small cell lung cancer
2024-517561-16-00Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan and zimberelimab in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Primary endpoint: Pathological complete response rate. Started Sep 2025; status: completed.
02
Drugs
sacituzumab govitecanzimberelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-517561-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517561-16-00.